+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • ID: 5589953
  • Report
  • April 2022
  • Region: Global
  • 527 Pages
  • Global Markets Direct
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • AbbVie Inc
  • Bio-Path Holdings Inc
  • Curis Inc
  • Incyte Corp
  • Mirati Therapeutics Inc
  • Seagen Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma - Drugs In Development, 2022, provides an overview of the Hodgkin Lymphoma (Oncology) pipeline landscape.

Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights


The Pharmaceutical and Healthcare latest pipeline guide Hodgkin Lymphoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 53, 44, 5, 21, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 7, 4, 3, 3 and 1 molecules, respectively.

Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (Oncology)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc
  • Bio-Path Holdings Inc
  • Curis Inc
  • Incyte Corp
  • Mirati Therapeutics Inc
  • Seagen Inc

IntroductionReport CoverageHodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Overview
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Companies Involved in Therapeutics DevelopmentHodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Drug ProfilesHodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant ProjectsHodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued ProductsHodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Product Development Milestones
Featured News & Press Releases
  • Apr 11, 2022: Glenmark Specialty S.A. receives approval for conducting phase 1 clinical trial of its novel molecule GRC 54276 in patients with advanced solid tumors and Hodgkin's lymphoma
  • Apr 10, 2022: Affimed presents updated clinical data from phase 1/2 study of AFM13 precomplexed with cord blood-derived NK cells at AACR Annual Meeting
  • Dec 14, 2021: Tessa Therapeutics announces positive data from phase 2 trial of autologous CD30-CAR-T therapy (TT11) in relapsed or refractory classical hodgkin lymphoma at 2021 ASH Annual Meeting
  • Dec 12, 2021: Seagen announces preliminary results from phase 2 clinical trial of ADCETRIS (brentuximab vedotin) in novel combination of agents for patients with advanced stage classical hodgkin lymphoma
  • Dec 09, 2021: Affimed to host virtual investor call today to discuss treatment of CD30-positive lymphoma patients with cord blood-derived natural killer cells pre-complexed with innate cell engager AFM13
  • Dec 02, 2021: BeiGene announces inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in three new indications
  • Dec 02, 2021: Innovent and Lilly announce successful expansion of Sintilimab in China National Reimbursement Drug List to include three additional first-line indications
  • Nov 04, 2021: Seagen to highlight multiple ADCETRIS (brentuximab vedotin) data presentations at the upcoming 2021 American Society of Hematology (ASH) Annual Meeting
  • Nov 03, 2021: Tessa Therapeutics announces presentation of autologous cell therapy data at 2021 ASH Annual Meeting
  • Sep 27, 2021: ONO receives approval of Opdivo (nivolumab) for dosage and administration for treatment of Pediatric Patients with Recurrent or Refractory Classical Hodgkin Lymphoma in Japan
  • Aug 30, 2021: Ligand’s partner Gloria Biosciences receives approval in China for zimberelimab for the treatment of recurrent or refractory classical Hodgkin’s lymphoma
  • Jun 22, 2021: ADC Therapeutics announces encouraging interim results from pivotal phase 2 clinical trial of Camidanlumab Tesirine (Cami) presented at the 16th Annual International Conference on Malignant Lymphoma
  • Jun 09, 2021: ADC Therapeutics announces presentation on Camidanlumab at the 16th Annual International Conference on Malignant Lymphoma
  • May 26, 2021: ADC Therapeutics announces online publication of Camidanlumab Tesirine phase 1 results in The Lancet Haematology
  • May 14, 2021: Tessa Therapeutics announces positive, topline data from ongoing phase 1 trial of allogeneic, “Off-the-Shelf” cell therapy, in patients with relapsed or refractory CD30-positive lymphoma
AppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact the Analyst
List of Tables
  • Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by AbbVie Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by ADC Therapeutics SA, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Adlai Nortye Biopharma Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Affimed GmbH, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Alfasigma SpA, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Angiocrine Bioscience Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Apollomics Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Astellas Pharma Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by AstraZeneca Plc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Aurigene Discovery Technologies Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Avipep Pty Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Bayer AG, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by BeiGene Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Bio-Path Holdings Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Bristol-Myers Squibb Co, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Carrick Therapeutics Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Catalent Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellectar Biosciences Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellectis SA, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Celleron Therapeutics Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellestia Biotech AG, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellular Biomedicine Group Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Celularity Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Checkmate Pharmaceuticals Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Checkpoint Therapeutics Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Chimeric Therapeutics Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by CSL Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by CStone Pharmaceuticals Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Curis Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Daiichi Sankyo Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Dyadic International Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Eutilex Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Faron Pharmaceuticals Oy, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Genentech USA Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Gibson Oncology LLC, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Gilead Sciences Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Glenmark Pharmaceuticals Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Guangzhou Sinogen Pharmaceutical Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Hangzhou Sumgen Biotech Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Hebei Senlang Biotechnology Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Helocyte Biosciences Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by HRAIN Biotechnology Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Hutchison MediPharma Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Immune Cell Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Incyte Corp, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Inhibrx Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Innovent Biologics Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Intellia Therapeutics Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Kymera Therapeutics Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by LegoChem Biosciences Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Luye Pharma Group Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Magenta Therapeutics Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Marker Therapeutics Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by MediSix Therapeutics Pte Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Merck & Co Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Merck KGaA, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Millennium Pharmaceuticals Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Miltenyi Biotec BV & Co KG, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Mirati Therapeutics Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by NewBio Therapeutics Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Northlake International LLC, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by OncoTartis Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Ono Pharmaceutical Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Pfizer Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by PlantForm Corp, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Protheragen Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rafael Pharmaceuticals Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by RAPT Therapeutics Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Regeneron Pharmaceuticals Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rhizen Pharmaceuticals SA, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rich Pharmaceuticals Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Sanofi, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Seagen Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai First Song Therapeutics Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shanghai YaKe Biotechnology Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shattuck Labs Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by SpecificiT Pharma Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Suzhou Everhealth Biomedical Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Syndax Pharmaceuticals Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Tacitus Therapeutics Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Tessa Therapeutics Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Tevogen Bio Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Tubulis GmbH, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Tyme Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Vincerx Pharma Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Viracta Therapeutics Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Waterstone Hanxbio Pty Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Xencor Inc, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, 2022
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products, 2022

List of Figures
  • Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Top 10 Routes of Administration, 2022
  • Number of Products by Stage and Top 10 Routes of Administration, 2022
  • Number of Products by Top 10 Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • AbbVie Inc
  • ADC Therapeutics SA
  • Adlai Nortye Biopharma Co Ltd
  • Affimed GmbH
  • Alfasigma SpA
  • Angiocrine Bioscience Inc
  • Apollomics Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Aurigene Discovery Technologies Ltd
  • Avipep Pty Ltd
  • Bayer AG
  • BeiGene Ltd
  • Bio-Path Holdings Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • Bristol-Myers Squibb Co
  • Carrick Therapeutics Ltd
  • Catalent Inc
  • Cellectar Biosciences Inc
  • Cellectis SA
  • Celleron Therapeutics Ltd
  • Cellestia Biotech AG
  • Cellular Biomedicine Group Inc
  • Celularity Inc
  • Checkmate Pharmaceuticals Inc
  • Checkpoint Therapeutics Inc
  • Chimeric Therapeutics Ltd
  • CSL Ltd
  • CStone Pharmaceuticals Co Ltd
  • Curis Inc
  • Daiichi Sankyo Co Ltd
  • Dyadic International Inc
  • Eutilex Co Ltd
  • Faron Pharmaceuticals Oy
  • Genentech USA Inc
  • Gibson Oncology LLC
  • Gilead Sciences Inc
  • Glenmark Pharmaceuticals Ltd
  • Guangzhou Sinogen Pharmaceutical Co Ltd
  • Hangzhou Sumgen Biotech Co Ltd
  • Harbin Gloria Pharmaceuticals Co Ltd
  • Hebei Senlang Biotechnology Co Ltd
  • Helocyte Biosciences Inc
  • HRAIN Biotechnology Co Ltd
  • Hutchison MediPharma Ltd
  • Immune Cell Inc
  • ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
  • Incyte Corp
  • Inhibrx Inc
  • Innovent Biologics Inc
  • Intellia Therapeutics Inc
  • Kymera Therapeutics Inc
  • LegoChem Biosciences Inc
  • Luye Pharma Group Ltd
  • Magenta Therapeutics Inc
  • Marker Therapeutics Inc
  • MediSix Therapeutics Pte Ltd
  • Merck & Co Inc
  • Merck KGaA
  • Millennium Pharmaceuticals Inc
  • Miltenyi Biotec BV & Co KG
  • Mirati Therapeutics Inc
  • NewBio Therapeutics Inc
  • Northlake International LLC
  • OncoTartis Inc
  • Ono Pharmaceutical Co Ltd
  • Pfizer Inc
  • PlantForm Corp
  • Protheragen Inc
  • Rafael Pharmaceuticals Inc
  • RAPT Therapeutics Inc
  • Regeneron Pharmaceuticals Inc
  • Rhizen Pharmaceuticals SA
  • Rich Pharmaceuticals Inc
  • Rizen (Suzhou) Biosciences Co Ltd
  • Sanofi
  • Seagen Inc
  • Shanghai First Song Therapeutics Co Ltd
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • Shanghai Pharmaceutical Group Co Ltd
  • Shanghai Pharmaceuticals Holding Co Ltd
  • Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
  • Shanghai YaKe Biotechnology Co Ltd
  • Shattuck Labs Inc
  • Shenzhen Chipscreen Biosciences Co Ltd
  • Sichuan Kelun Pharmaceutical Co Ltd
  • SpecificiT Pharma Inc
  • Suzhou Everhealth Biomedical Co Ltd
  • Syndax Pharmaceuticals Inc
  • Tacitus Therapeutics Inc
  • Takeda Pharmaceutical Co Ltd
  • Tessa Therapeutics Ltd
  • Tevogen Bio Inc
  • Tubulis GmbH
  • Tyme Inc
  • Vincerx Pharma Inc
  • Viracta Therapeutics Inc
  • Waterstone Hanxbio Pty Ltd
  • Wuhan Bio-Raid Biotechnology Co Ltd
  • Xencor Inc
Note: Product cover images may vary from those shown